JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

Merus NV

Gesloten

SectorGezondheidszorg

67.24 0.6

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

65.94

Max

67.24

Belangrijke statistieken

By Trading Economics

Inkomsten

-66M

-96M

Verkoop

17M

26M

EPS

-1.4

Winstmarge

-364.218

Werknemers

260

EBITDA

-4.5M

-93M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+41.49% upside

Dividenden

By Dow Jones

Volgende Winsten

6 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.4B

5B

Vorige openingsprijs

66.64

Vorige sluitingsprijs

67.24

Nieuwssentiment

By Acuity

50%

50%

176 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Merus NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 aug 2025, 23:11 UTC

Winsten

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5 aug 2025, 22:45 UTC

Winsten

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5 aug 2025, 22:39 UTC

Winsten

Great-West Lifeco Logs Lower 2Q Profit

5 aug 2025, 21:32 UTC

Winsten

Coupang Posts Higher 2Q Sales Due to Customer Growth

6 aug 2025, 00:00 UTC

Acquisities, Fusies, Overnames

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6 aug 2025, 00:00 UTC

Acquisities, Fusies, Overnames

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6 aug 2025, 00:00 UTC

Acquisities, Fusies, Overnames

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6 aug 2025, 00:00 UTC

Acquisities, Fusies, Overnames

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5 aug 2025, 23:48 UTC

Marktinformatie

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5 aug 2025, 23:40 UTC

Marktinformatie

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5 aug 2025, 23:19 UTC

Marktinformatie

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5 aug 2025, 23:03 UTC

Marktinformatie
Winsten

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5 aug 2025, 22:22 UTC

Winsten

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5 aug 2025, 22:21 UTC

Winsten

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5 aug 2025, 22:20 UTC

Winsten

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5 aug 2025, 22:18 UTC

Winsten

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5 aug 2025, 22:17 UTC

Winsten

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5 aug 2025, 22:17 UTC

Winsten

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5 aug 2025, 22:16 UTC

Winsten

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5 aug 2025, 22:16 UTC

Winsten

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5 aug 2025, 22:15 UTC

Winsten

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5 aug 2025, 22:13 UTC

Winsten

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5 aug 2025, 22:13 UTC

Winsten

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5 aug 2025, 22:12 UTC

Winsten

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5 aug 2025, 22:12 UTC

Winsten

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5 aug 2025, 21:58 UTC

Winsten

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 aug 2025, 21:30 UTC

Winsten

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5 aug 2025, 21:26 UTC

Winsten

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5 aug 2025, 21:23 UTC

Winsten

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5 aug 2025, 21:17 UTC

Winsten

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Peer Vergelijking

Prijswijziging

Merus NV Prognose

Koersdoel

By TipRanks

41.49% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 94.7 USD  41.49%

Hoogste 110 USD

Laagste 67 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Merus NV - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

13

Buy

0

Hold

0

Sell

Technische score

By Trading Central

39.445 / 44.36Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Neutral Evidence

Sentiment

By Acuity

176 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Merus NV

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.